Clinical Trials Logo

Hydrocephalus clinical trials

View clinical trials related to Hydrocephalus.

Filter by:

NCT ID: NCT05762848 Completed - Clinical trials for Hydrocephalus in Infants

Clinical Application and Functionality for an Application for Measurement of Head Circumference.

Start date: November 1, 2022
Phase:
Study type: Observational

Title of clinical study:Clinical application, validation, and functionality evaluation of the Mobile Head Circumference Application in neonates and children Sponsor: University Hospitals NHS Foundation Trust Purpose of study:Evaluate and validate the utility of the mobile Head Circumference application for use in the clinical and outpatient setting for evaluation of head circumference of neonates and infants Primary objectives:Evaluate usefulness of and feasibility of the application in the clinical setting comparing it to normal practice. Secondary objectives:Evaluate parent/guardian reliability and satisfaction of the use of the mobile head circumference app. Study Design:Prospective Sample Size:Treating clinicians employed by Cambridge University Hospitals NHS Foundation Trust will identify patients eligible for this study (infants <18 months of age) and notify research team members with the patient's/guardian's consent. Once identified, research team members will approach patients' parents/guardians to seek informed consent before their clinic appointment or at the bedside on the ward. An information sheet will be used. If they choose to participate, we will measure the HC during the clinic appointment or on the ward. (Please refer to Flowchart 1). Sample size estimation was calculated with 90% statistical power to detect a change of means by 1 and a standard deviation of 1. This, along with 10% iteration, equals 33 participants. Summary of eligibility criteria:Neonatal patients and infants with need of continuous measurement of Head Circumference up to the age of 18months. Investigational techniques:Mobile application for Automatic measurement of head circumference.

NCT ID: NCT05679934 Recruiting - Clinical trials for NPH (Normal Pressure Hydrocephalus)

The Effects of Exercise on Gait Characteristics, Balance, and Performance in Patients With Normal Pressure Hydrocephalus

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The goal of this study is to investigate effect of exercise program on balance, gait and performance in patients with normal pressure hydrocephalus applied with lumbar puncture. The main question it aims to answer are: - Home based exercise program effective on balance, gait and performance - Telerehabilitation exercise program effective on balance, gait and performance Researchers will compare home based exercise group, telerehabilitation group and control group to see if difference in terms of balance, gait and performance

NCT ID: NCT05562596 Not yet recruiting - Clinical trials for Cognitive Impairment

Normal Pressure Hydrocephalus Biomarkers Investigation

NORPHY
Start date: October 30, 2022
Phase:
Study type: Observational

Normal Pressure Hydrocephalus (NPH) is a clinical condition that induces cognitive deterioration that can be reverted, at least in part, by introducing ventricular-peritoneal diversion controlled by a miniaturized valve system. Mechanisms involved in such an improvement of cognitive function after liquor diversion are unknown. Oxysterols are a family of cholesterol-related compounds having diverse biological functions. Among others, they are involved in cholesterol homeostasis in the brain and are detectable in liquor, potentially impacting neurodegeneration. NPH is an ideal clinical model to study oxysterol distribution in liquor before and after ventricular-peritoneal diversion.

NCT ID: NCT05546996 Recruiting - Hydrocephalus Clinical Trials

EVD Drainage Data and Intracranial Pressure (ICP) Measurements

RHAEOS
Start date: July 11, 2023
Phase: N/A
Study type: Interventional

Rhaeos, Inc. is initially targeting hydrocephalus, a life threatening condition caused by an abnormal accumulation of cerebrospinal fluid (CSF). Implantable shunts, the gold standard treatment, often fail, leading to multiple trips to the emergency room and repeat surgeries. There is no technology available today that can easily assess CSF flow in shunts wirelessly, bedside, and without capital equipment until now. FlowSense, is a wireless, noninvasive thermal flow sensor that can be mounted on a patient's neck overlying the shunt to detect the presence and magnitude of CSF. Similar in size to a bandage, it is composed of soft, silicone with no hard edges. Data is wirelessly transmitted to a custom designed mobile app. With FlowSense, monitoring of shunt function can occur in clinics, in-patient settings, and emergency departments, thereby reducing unnecessary imaging, hospital length of stay, and readmission costs.

NCT ID: NCT05544279 Recruiting - Hydrocephalus Clinical Trials

Caregiver Burden and Anxiety in Mothers of Children With Hydrocephalus

Start date: July 17, 2020
Phase: N/A
Study type: Interventional

This study is being conducted in randomized controlled trial design to determine the effect of the education given to the mothers of children with hydrocephalus on caregiver burden and anxiety levels.

NCT ID: NCT05534659 Completed - Hydrocephalus Clinical Trials

Comparison of Programmable and Non-programmable CSF Shunts Among Adult Hydrocephalus Patients With Different Etiologies

Start date: January 1, 2017
Phase:
Study type: Observational

Programmable valve (PV) has been shown as a solution to the high revision rate in pediatric hydrocephalus patients, but it remains controversial among adults. This study is to compare the overall revision rate, revision cause, and revision-free survival between PV and non-programmable valve (NPV) in adult patients with different hydrocephalus etiologies.

NCT ID: NCT05501002 Terminated - Hydrocephalus Clinical Trials

Pilot Study to Evaluate the CereVasc® eShunt® System in the Treatment of Communicating Hydrocephalus

Start date: September 15, 2022
Phase: N/A
Study type: Interventional

The purpose of this study will be to evaluate a novel, minimally invasive method of treating hydrocephalus in adults. The eShunt® System includes a proprietary eShunt® Delivery System and the eShunt® Implant, a permanent implant that is deployed in a mildly invasive, neuro-interventional procedure. The eShunt® Implant is designed to drain excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system.

NCT ID: NCT05476874 Recruiting - Hydrocephalus Clinical Trials

Improvement of Peritoneal Catheter Placement in VPS With a Splitable Trocar

Start date: January 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a phase I/IIa, single-center, open-labeled, randomized, controlled clinical trial. The aim of this study is to evaluate the safety and efficacy of a modified ventriculoperitoneal catheter placement using a splitable trocar for ventriculoperitoneal shunt.

NCT ID: NCT05432986 Completed - Hydrocephalus Clinical Trials

Assessment of CSF Shunt Flow With Thermal Measurements B

STEALTH
Start date: July 7, 2022
Phase:
Study type: Observational

This study evaluates the performance of a non-invasive thermal measurement device for assessing CSF shunt flow. Patients with an existing implanted shunt and symptoms of shunt malfunction will be evaluated with the study device.

NCT ID: NCT05399602 Recruiting - Hydrocephalus Clinical Trials

The Role of Neurofilament Light (NfL) in Patients With Hydrocephalus

Start date: December 7, 2023
Phase: N/A
Study type: Interventional

Neurofilament Light Chain Protein (NfL) has been found by many studies as a sensitive biomarker of neuronal damage from several reasons, e.g. neurodegenerative diseases (Alzheimer's disease, Multiple Sclerosis, etc.), inflamation (HIV) or trauma. Its role as biomarker thus offers a possibility to predict and manage diseases associated with neuronal damage. Therefore our aim is to investigate the changes in level of NfL in hydrocephalus and to find its role in management of treatment in hydrocephalus.